Population Pharmacokinetic Analysis of Micafungin in Japanese Patients with Fungal Infections
-
- TABATA Kenji
- Analysis & Pharmacokinetics Research Labs., Astellas Pharma. Inc.
-
- KATASHIMA Masataka
- Clinical Pharmacology, Astellas Pharma. Inc.
-
- KAWAMURA Akio
- Drug Metabolism Research Labs., Astellas Pharma. Inc.
-
- KAIBARA Atsunori
- Clinical Pharmacology, Astellas Pharma. Inc.
-
- TANIGAWARA Yusuke
- Department of Hospital Pharmacy, School of Medicine Keio University
この論文をさがす
抄録
The object of this analysis was to develop a population pharmacokinetic model of micafungin, a new anti-fungal agent of the echinocandin class, to optimize dosing in Japanese patients with fungal infections. Population pharmacokinetics parameters were determined using NONMEM based on pharmacokinetic data from 198 subjects in seven clinical studies, comprising four phase I, two phase II and one pediatric phase III study. The healthy subjects received intravenous infusion of 2.5-150 mg micafungin. Adult and pediatric patients, age range of 8 month to 15 yeras old, were received 25-150 mg and 1-6 mg/kg daily, respectively. A total of 1825 micafungin plasma samples were available for this analysis. Two-compartment pharmacokinetic model was adopted. The clearance of micafungin was influenced by body weight in children and platelet counts (PLT). However the PLT accounted for less than 20% of the variation of micafungin clearance in Japanese subjects. In conclusions, body weight is the primary covariate factor in pediatric patients. The dose adjustment by body weight would be required only pediatric patients for the micafungin therapy in Japanese patients with fungal infection.<br>
収録刊行物
-
- Drug Metabolism and Pharmacokinetics
-
Drug Metabolism and Pharmacokinetics 21 (4), 324-331, 2006
日本薬物動態学会
- Tweet
詳細情報
-
- CRID
- 1390001205178758016
-
- NII論文ID
- 10018042991
-
- NII書誌ID
- AA1162652X
-
- ISSN
- 18800920
- 13474367
-
- 本文言語コード
- en
-
- データソース種別
-
- JaLC
- Crossref
- CiNii Articles
-
- 抄録ライセンスフラグ
- 使用不可